The Food and Drug Administration’s announcement last August that it would randomly retest 20 popular generic drugs now on the market, add $18 million for field operations and intensify company surveillance came on the heels of a year-long congressional investigation of the agency. The FDA was responding – some critics say too late – to a drug scandal that both hampered FDA goals of regulating an industry and shook agency management. …
Read more: FDA Reorganizes amid Generic Drug Scandal